Key Events This Week
1 June: Valuation shifts from attractive to fair, P/E at 18.58
2 June: Technical momentum shifts from strongly bearish to mildly bearish
5 June: Week closes at ₹75.86, down 1.34%
Jun 19, 03:30 PM
BSE+NSE Vol: 64.5 k

Anuh Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Anuh Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a 4.34% gain on 15 Jun 2026, the micro-cap pharmaceutical stock continues to face mixed signals from key momentum and trend indicators, underscoring the challenges investors face in navigating its near-term outlook.
Read full news article
1 June: Valuation shifts from attractive to fair, P/E at 18.58
2 June: Technical momentum shifts from strongly bearish to mildly bearish
5 June: Week closes at ₹75.86, down 1.34%

Anuh Pharma Ltd (Stock ID: 905552) has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend across multiple timeframes. Despite a micro-cap status and a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s price action and technical parameters warrant close examination for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
Anuh Pharma Ltd has exhibited a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent market data and technical indicators. Despite a modest day gain of 2.62%, the stock’s broader technical signals present a complex picture, with mixed readings from MACD, RSI, moving averages, and other momentum oscillators, suggesting cautious investor sentiment amid ongoing volatility.
Read full news article
Anuh Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 09 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a bearish trend. Recent technical indicators including MACD, RSI, Bollinger Bands, and moving averages signal increasing downside pressure, while mixed signals from KST and Dow Theory add complexity to the stock’s near-term outlook.
Read full news article
Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day decline of 0.23%, the stock’s technical indicators reveal a complex picture with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, suggesting cautious optimism tempered by underlying weaknesses.
Read full news article
Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid sector dynamics and peer comparisons, with key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios signalling a recalibration of price attractiveness.
Read full news articleNewspaper Publication for transfer of equity shares of the Company for which Dividend has not been claimed by shareholders for seven consecutive years or more to Investor Education and Protection Fund (IEPF) published in Financial Express (English) and Mumbai Lakshdeep (Marathi).
Disclosure under Regulation 30 of the SEBI LODR regarding receipt of Demand Order under Section 156 and Penalty Order under Section 270 of the Income Tax Act 1961.
Submission of Annual Secretarial Compliance Report for the Financial Year ended 31st March 2026.
No Upcoming Board Meetings
Anuh Pharma Ltd has declared 30% dividend, ex-date: 14 Aug 25
Anuh Pharma Ltd has announced 5:10 stock split, ex-date: 31 Jul 06
Anuh Pharma Ltd has announced 1:1 bonus issue, ex-date: 15 Jul 25
No Rights history available